Comparative Pharmacology
Head-to-head clinical analysis: GONAL F RFF versus METRODIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F RFF versus METRODIN.
GONAL-F RFF vs METRODIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates pituitary gonadotropin release, then downregulates GnRH receptors, suppressing LH and FSH secretion.
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Terminal elimination half-life is approximately 35 hours (range 28–48 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Primarily renal, with approximately 75% of a dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for less than 5% of elimination.
Category C
Category C
Gonadotropin
Gonadotropin